Table 2.
Correlation of MALT1 expression with clinical characteristics in RA patients.
| Characteristics | MALT1 expressionMedian (IQR) | Correlation coefficient (rs ) | P value |
|---|---|---|---|
| Age | – | 0.076 | 0.363 |
| BMI | – | 0.115 | 0.167 |
| Disease duration | – | 0.113 | 0.173 |
| TJC | – | 0.137 | 0.098 |
| SJC | – | 0.110 | 0.183 |
| ESR | – | 0.240 | 0.003 |
| CRP | – | 0.298 | <0.001 |
| DAS28ESR score | – | 0.242 | 0.003 |
| CDAI score | – | 0.179 | 0.030 |
| HAQ-DI score | – | 0.128 | 0.121 |
| Gender | – | 0.555 | |
| Male | 2.604 (2.007-4.308) | ||
| Female | 2.476 (1.716-3.654) | ||
| RF positive | – | 0.112 | |
| No | 2.676 (1.912-5.433) | ||
| Yes | 2.476 (1.724-3.510) | ||
| ACPA positive | – | 0.060 | |
| No | 2.679 (2.179-3.871) | ||
| Yes | 2.411 (1.623-3.500) | ||
| History of NSAID | – | 0.263 | |
| No | 2.086 (1.400-3.598) | ||
| Yes | 2.566 (1.789-3.672) | ||
| History of GC | – | 0.678 | |
| No | 2.466 (1.648-3.887) | ||
| Yes | 2.557 (1.729-3.672) | ||
| History of csDMARDs | – | 0.267 | |
| No | 2.086 (1.552-2.641) | ||
| Yes | 2.566 (1.773-3.673) | ||
| History of bDMARDs | – | 0.732 | |
| No | 2.513 (1.807-3.593) | ||
| Yes | 2.602 (1.576-3.763) | ||
| Current treatment: csDMARDs combination | – | 0.116 | |
| No | 2.527 (2.061-4.137) | ||
| Yes | 2.554 (1.616-3.531) | ||
| Current treatment: bDMARDs with/without csDMARDs | – | 0.116 | |
| No | 2.554 (1.616-3.531) | ||
| Yes | 2.527 (2.061-4.137) |
MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; RA, rheumatoid arthritis; IQR, interquartile range; BMI, body mass index; TJC, tender joint count; SJC, swollen joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28ESR, disease activity score 28 based on erythrocyte sedimentation rate; CDAI, clinical disease activity index; HAQ-DI, health assessment questionnaire disability index; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide antibody; NSAID, non-steroidal anti-inflammatory drug; GC, glucocorticoid; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; bDMARDs, biological disease-modifying antirheumatic drugs.
Bold values meant statistical significance (P < 0.05).